Levi & Korsinsky announces it has commenced an investigation of Geron Corporation ("Geron" or "the Company") (NASDAQGS: GERN) concerning possible violations of federal securities laws. On March 27, 2017, STAT published a report by Adam Feuerstein stating that Geron's recent stock gains were due to "flimsy" claims regarding the efficacy of imetelstat, Geron's experimental treatment for myelofibrosis. The report states that available data for imetelstat undercuts Geron's representations concerning the drug's efficacy. Following this news, shares of Geron have fallen from a close of $5.98 on March 26, 2018, to a recent close of $4.02 on April 2, 2018. To obtain additional information, go to: http://www.zlkdocs.com/GERN-Info-Request-Form-6580 or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.